Journal
MOLECULAR CELL
Volume 19, Issue 2, Pages 159-170Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2005.06.009
Keywords
-
Categories
Funding
- NCI NIH HHS [P01 CA099031, CA 16672, R01 CA58880, R01 CA109311] Funding Source: Medline
Ask authors/readers for more resources
beta-catenin is upregulated in many human cancers and considered to be an oncogene. Hepatocellular carcinoma (HCC) is one of the most prevalent human malignancies, and individuals who are chronic hepatitis B virus (HBV) carriers have a greater than 100-fold increased relative risk of developing HCC. Here we report a mechanism by which HBV-X protein (HBX) upregulates beta-catenin. Erk, which is activated by HBX, associates with GSK-3 beta through a docking Motif ((FKFP)-F-291) of GSK-3 beta and phosphorylates GSK-3 beta at the (43)Thr residue, which primes GSK-3 beta for its subsequent phosphorylation at Ser9 by p90RSK, resulting in inactivation of GSK-3 beta and upregulation of P-catenin. This pathway is a general signal, as it was also observed in cell lines in which Erk-primed inactivation of GSK-3 beta was regulated by IGF-1, TGF-beta, and receptor tyrosine kinase HER2, and is further supported by immunohistochemical staining in different human tumors, including cancers of the liver, breast, kidney, and stomach.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available